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Objective: To estimate the cost-effectiveness of using an extensively hydrolyzed casein formula 
(eHCF) containing the probiotic Lactobacillus rhamnosus GG, (eHCF + LGG; Nutramigen LGG) 
as first-line management for cow’s milk allergy (CMA) compared with eHCF alone, soy-based 
formulae (SBF), hydrolyzed rice formulae (HRF), and amino acid formulae (AAF) in Italy, from 
the perspective of the Italian National Health Service (INHS) and parents.
Methods: Decision modeling was used to estimate the probability of infants developing tol-
erance to cow’s milk by 18 months, based on an observational study dataset. The model also 
estimated the cost (at 2012/2013 prices) of health care resource use funded by the INHS and 
formulae paid for by parents over 18 months after starting a formula, as well as the relative 
cost-effectiveness of each of the formulae.
Results: The probability of developing tolerance to cow’s milk by 18 months was higher among 
infants with either IgE-mediated or non-IgE-mediated allergy who were fed eHCF + LGG 
compared to those fed one of the other formulae. The total health care cost of initially feeding 
infants with eHCF + LGG was less than that of feeding infants with one of the other formulae. 
Hence, eHCF + LGG affords the greatest value for money to both the INHS and parents of 
infants with either IgE-mediated or non-IgE-mediated CMA.
Conclusion: Using eHCF + LGG instead of eHCF, SBF, HRF, or an AAF for first-line man-
agement of newly diagnosed infants with CMA in Italy affords a cost-effective use of publicly 
funded resources, and is cost-effective from the parents’ perspective, since it improves outcome 
for less cost. A randomized controlled study showing faster tolerance development in children 
receiving a probiotic-containing formula is required before this conclusion can be confirmed.
Keywords: amino acid formula, extensively hydrolyzed formula, soy-based formulae, hydro-
lyzed rice formulae
Introduction
Cow’s milk allergy (CMA) is one of the most common food allergies in early child-
hood, with an estimated incidence ranging between 0.02 and 0.03.1,2 Recent evidence 
suggests that the natural history of this allergy is changing, with an increased risk of 
persistence until later ages3,4 and severity.1,5 Guidelines addressing the management 
of infants with CMA recommend the use of substitutive hypoallergenic formulae.6,7 
However, the potential impact of these formulae on disease duration has historically 
not been considered due to a lack of comparative data.
In a recent observational study, the addition of the probiotic Lactobacillus 
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Nutramigen LGG) was found to accelerate the development 
of tolerance in infants with CMA compared with those receiv-
ing eHCF alone, soy-based formulae (SBF), hydrolyzed rice 
formulae (HRF), or amino acid formulae (AAF).8 The study’s 
findings are consistent with a previous study.9
The comparative health economic impact of these differ-
ent formulae is unknown, and therefore, dietetic choices are 
based largely on their safety, nutritional value, and purchase 
cost. Hence, the objective of the current study was to use data 
from the aforementioned observational study8 to estimate 
the cost-effectiveness of using eHCF + LGG as a first-line 
formula for CMA compared with eHCF, HRF, SBF, and 
AAF in Italy, from the perspective of the Italian National 
Health Service (INHS) and parents.
Methods
Economic model
A decision model was constructed using TreeAge Pro 2009 
(TreeAge Software Inc., Williamstown, MA, USA) depict-
ing the management of infants with CMA who are man-
aged first-line with eHCF + LGG, eHCF, SBF, HRF, or an 
AAF. The model was populated with 1) the patient-level data 
from the aforementioned observational study,8 kindly provided 
by the authors of the study and 2) estimates of health care 
resource use derived from interviews with Italian pediatricians. 
The period of the model was up to 18 months or when an infant 
developed tolerance to cow’s milk if that occurred earlier.
Model inputs – clinical outcomes
The observational study was an open, nonrandomized 
intervention conducted between July 2010 and June 2012. 
The study prospectively evaluated otherwise healthy infants 
(n=260; mean age at recruitment of 5.92 months; 64% male; 
mean body weight 6.66 kg; 43% with IgE-mediated CMA) 
who were referred to a tertiary pediatric allergy center for a 
diagnostic double-blind, placebo-controlled food challenge 
(DBPCFC) for suspected CMA 15–30 days after starting 
a formula. Prior to referral, all infants had been managed 
with a formula that was selected and prescribed by a fam-
ily pediatrician or physician. Management following study 
entry did not vary depending upon formula type. Infants 
were excluded from the study if they were fed a pre-probiotic 
product in the previous 4 weeks or if they experienced cow 
milk protein–induced anaphylaxis, eosinophilic disorders of 
the gastrointestinal tract, food protein–induced enterocolitic 
syndrome, or other chronic comorbidities.8
The endpoint of the study was the percentage of infants 
who developed tolerance to cow’s milk at 12 months from 
the start of a formula. Tolerance was confirmed following 
the results of a full anamnestic and clinical evaluation, skin 
prick test, atopy patch test, and oral food challenge.8 All 
food challenges were performed in a DBPCFC manner. 
Clinical acquisition of tolerance was defined by the pres-
ence of a negative DBPCFC over a 7-day post-challenge 
observation period. Infants with negative DBPCFC were 
reevaluated after 6 months to check the persistence of toler-
ance to cow’s milk.
The study found that significantly more infants in the 
eHCF + LGG group developed oral tolerance to cow’s milk 
after 12 months (78.9%; P,0.05) compared with those fed 
with one of the other formulae: eHCF (43.6%), HRF (32.6%), 
SBF (23.6%), and AAF (18.2%). Binary logistic regression 
revealed that the rate of infants developing tolerance at the 
end of the study was influenced by both IgE-mediated mecha-
nism (odds ratio: 0.12; P,0.001) and choice of eHCF + LGG 
formula (odds ratio: 28.62; P,0.001). Time series forecast-
ing was used to extrapolate the probability of developing 
tolerance to cow’s milk with each formula up to 18 months. 
These percentages were used to populate the model with the 
probability of infants developing tolerance to cow’s milk at 
6-monthly intervals up to 18 months.
Model inputs – resource use
The model was populated with estimates of health care 
resource use pertaining to the management of infants with 
CMA in Italy. These estimates were derived from a series 
of interviews with five Italian pediatricians who managed 
infants with CMA according to the recommendations of 
the Diagnosis and Rationale for Action against Cow’s Milk 
Allergy (DRACMA)10 and the National Institute for Health 
and Care Excellence (NICE).11
The interviewed general pediatricians each saw a mean 
of ,20 infants with suspected CMA per annum, with a 
mean age at presentation of ∼5 months (range 3–6 months). 
According to the interviewees, ∼75% of infants would have 
their CMA diagnosed by a general pediatrician. The other 
25% of infants would be referred to a pediatric specialist 
for further investigations and confirmation of diagnosis. 
Time from referral to seeing a pediatric specialist would 
be ∼1 week. The interviewed pediatric specialists each saw a 
mean of 300 infants with CMA per annum, with a mean age 
at presentation of ∼6 months (range: 2–9 months). Estimates 
of resource use derived from the clinician interviews were 
incorporated into the model.
According to the interviewees, an infant would generally 
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ehCF containing lgg in managing cow’s milk allergy in italian infants
and ∼2 weeks after the initial visit to a pediatric specialist. 
The infants would not generally receive other prescriptions 
(such as for gastrointestinal drugs and topical medication) 
for CMA.
In Italy, parents of affected infants pay for prescriptions 
of nutritional formulae. However, the prescriptions may be 
free, depending on the region, when CMA is associated with 
other comorbidities such as malnutrition or there is evidence 
of anaphylaxis.
The interviewed physicians prescribe formula based on an 
infants’ age and weight. Hence, up to 3 months of age, infants 
received ∼150 mL/kg/day (500–1,000 mL/day) decreasing 
to ∼120 mL/kg/day (800–900 mL/day) at 6 months of age. 
Between 7 and 9 months of age, infants received ∼600 mL/
day, decreasing to ∼400 mL/day at .1 year of age.
In accordance with the infants’ age in the study, infants 
enter the model at a mean age of 5.92 months. Hence, it was 
estimated that infants would be prescribed: 48×400 g cans of 
formula in the first 6 months of the model, 36×400 g cans 
of formula in the next 6 months of the model, and 36×400 g 
cans of formula between 13 and 18 months.
statistical analyses
Using analysis of covariance (ANCOVA), differences in 
tolerance acquisition between formulae were adjusted for 
any differences in the following baseline variables: age, sex, 
presenting symptoms, and baseline values of the diagnostic 
tests. The analysis found that the five groups were balanced 
and no adjustments were necessary. All statistical analyses 
were performed using IBM SPSS software (v21.0; IBM 
Corporation, Armonk, NY, USA).
Model outputs
The primary measure of clinical effectiveness was the 
probability of infants developing tolerance to cow’s milk 
by 18 months.
Unit costs at 2012/2013 prices12 were assigned to the 
estimates of resource use in the model in order to calculate 
the cost over 18 months from starting a formula of:
 health care resource use funded by the INHS and
 formulae paid for by parents.
The model was used to estimate the cost-effectiveness 
of using one formula compared with another in terms of 
the incremental cost per additional infant who developed 
tolerance to cow’s milk by 18 months in Italy. This was 
calculated as the difference between the expected costs of 
the two dietetic strategies divided by the difference between 
the expected outcomes of the two strategies in terms of the 
probability of developing tolerance to cow’s milk. If one of 
the formulae improved the probability of developing toler-
ance to cow’s milk for less cost, it was considered to be the 
dominant (cost-effective) dietetic strategy.
sensitivity analyses
To assess uncertainty within the model, probabilistic sen-
sitivity analysis was undertaken (100,000 iterations of the 
model) by simultaneously varying the probabilities, clinical 
outcomes, resource use values, and unit costs within the 
model. A beta distribution was used to represent uncertainty 
in probability values by assuming a 5% standard deviation 
around the mean values. Clinical outcomes and resource use 
estimates were varied randomly according to a log-normal 
distribution by assuming a 5% standard deviation around the 
mean values. Unit costs were varied randomly according to 
a gamma distribution by assuming a 10% standard deviation 
around the mean values. The outputs from these analyses 
were used to estimate the probability of being cost-effective 
at different thresholds of cost per additional infant who 
developed tolerance to cow’s milk by 18 months.
In addition, deterministic sensitivity analyses were per-
formed to identify how the incremental cost-effectiveness of 
one strategy over the other would change by varying different 
parameters in the model. The budget impact and resource 
implications of starting infants with eHCF + LGG compared 
to current practice were also estimated for the annual cohort 
of newly diagnosed infants with CMA in Italy.
Results
Probability of developing  
tolerance to cow’s milk
The probability of developing tolerance to cow’s milk 
was higher among infants who were initially fed with 
eHCF + LGG (Figure 1). Also, the probability of develop-
ing tolerance to cow’s milk was higher among those infants 
with non-IgE-mediated CMA compared to those with IgE-
mediated allergy.
health care resource use  
and corresponding costs
An infant who is initially managed with eHCF + LGG 
is expected to consume fewer health care resources than 
infants managed with the other formulae (Table 1). Hence, 
initially feeding infants with eHCF + LGG instead of the 
other formulae is expected to free-up health care resources 
for alternative use by other patients. Consequently, the total 


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1


















eHCF SBF HRF AAF eHCF +
LGG
eHCF SBF HRF AAF







































Figure 1 Expected probability of infants developing tolerance to cow’s milk by 18 months after starting a formula.
Abbreviations: aaF, amino acid formula; ehCF, extensively hydrolyzed casein formula; hRF, hydrolyzed rice formula; lgg, Lactobacillus rhamnosus gg; sBF, soy-based formula.
is expected to be less than that of feeding infants with one of 
the other formulae (Table 1). Similarly, the cost to parents 
of infants managed with eHCF + LGG is expected to be 
less than that to parents of infants fed with one of the other 
formulae (Table 1).
Cost-effectiveness analyses
From the inhs’ perspective
Of the five formulae, use of eHCF + LGG resulted in a lower 
18-month cost and a greater probability of developing toler-
ance than the other four formulae among infants with both 
IgE-mediated and non-IgE-mediated CMA. Hence, starting 
feeding with this formula was found to be the dominant 
strategy.
Among infants with IgE-mediated CMA, initial feeding 
with eHCF was found to be a dominant strategy when com-
pared to starting feeding with SBF, HRF, or an AAF. The 
analysis also found that:
 initially feeding infants with SBF was a dominant strategy 
when compared to starting feeding with HRF or an AAF;
 initially feeding infants with HRF was a dominant strategy 
compared to an AAF.
Among infants with non-IgE-mediated CMA, initially 
feeding with eHCF was a dominant strategy when compared 
to starting feeding with SBF, HRF, or an AAF. The analysis 
also found that:
 Initially feeding infants with an AAF instead of SBF 
increased the probability of developing tolerance to cow’s 
milk by 0.003, but increased INHS costs by €2. Hence, the 
cost for each additional patient who developed tolerance 
to cow’s milk with AAF was €667.
 Initially feeding infants with HRF instead of an AAF 
increased the probability of developing tolerance to cow’s 
milk by 0.237, but increased INHS costs by €4. Hence, the 
cost for each additional patient who developed tolerance 
to cow’s milk with HRF was €17.
From parents’ perspective
From the parents’ perspective, eHCF + LGG is the preferred 
dietetic choice for both infants with IgE-mediated and non-
IgE-mediated CMA, since it improved outcome for less cost 
(ie the dominant formula).
sensitivity analyses
Probabilistic sensitivity analyses were performed to esti-
mate the distribution of expected INHS costs (Figure 2) 
and parents’ costs (Figure 3) over 18 months from starting 
a formula and probability of developing tolerance to cow’s 
milk by 18 months. Using these distributions, the probabil-
ity of each formula being cost-effective at different cost-
 effectiveness thresholds was estimated (Figures 4 and 5). 
These graphs showed that the probability of eHCF + LGG 
being cost-effective was greater than with the other formulae 
for both IgE-mediated and non-IgE-mediated allergic infants, 
from the perspective of both the health service and parents. 
 Moreover, these graphs suggest that neither eHCF, SBF, 
HRF, nor AAF would afford a cost-effective use of resources 
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These analyses also indicate that eHCF + LGG affords 
the greatest value for money to the INHS followed by 
eHCF, SBF, HRF, and AAF in that order for managing 
infants with IgE-mediated allergy, but followed by eHCF, 
HRF, SBF, and AAF in that order for managing infants with 
non-IgE-mediated allergy. From the parents’ perspective, 
eHCF + LGG affords the greatest value for money followed 
by SBF, HRF, eHCF, and AAF in that order for managing 
infants with IgE-mediated allergy, but followed by HRF, 
SBF, eHCF, and AAF in that order for managing infants with 
non-IgE-mediated allergy. Irrespective of the perspective, 
eHCF + LGG is ranked as the preferred formula, and AAF 
the last formula of choice.
Deterministic sensitivity analyses (Table 2) demonstrated 
that inclusion/exclusion of the probability of developing tol-
erance to cow’s milk after 12 months has minimal impact on 
the results. However, exclusion of the probability of develop-
ing tolerance to cow’s milk after 6 months has the potential 
to yield misleading results. Additionally, changes in resource 
use can potentially change costs incurred by the INHS, but 
they are unlikely to change the ranking of dietetic choices. 
The relative cost-effectiveness of the five formulae was not 
sensitive to changes in any other model input.
Budget impact and resource implications 
of using ehCF + lgg
There are an estimated 0.53 million live births in Italy per 
annum13 and the incidence of CMA is reported to be 0.025.1,2 
Hence, there are an estimated 16,000 new CMA-affected 
infants per annum in Italy. Assuming the distribution of 
formula use is as depicted in the aforementioned study,8 
current management of all 16,000 newly diagnosed infants 
results in 52% of the cohort developing tolerance to cow’s 
milk by 18 months, 46,300 visits to pediatricians, and a cost 
to the INHS of €2.83 million. If all these infants were initially 
managed with eHCF + LGG, it is expected that 84% of the 
cohort would develop tolerance to cow’s milk by 18 months, 
there would be 5,300 fewer visits to pediatricians, and a cost 
reduction to the INHS of €0.35 million.
If the budget impact analysis only considered a period of 
12 months following the start of a formula, current manage-
ment of all 16,000 newly diagnosed infants results in 44% of 
the cohort developing tolerance to cow’s milk by 12 months, 
39,500 visits to pediatricians, and a cost to the INHS of 
€2.49 million. If all these infants were initially managed with 
eHCF + LGG, it is expected that 84% of the cohort would 
develop tolerance to cow’s milk by 12 months, there would 
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Figure 2 (A) Distribution of expected inhs costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months 
among igE-mediated allergic infants, generated by 100,000 iterations of the model. (B) Distribution of expected inhs costs over 18 months from starting a formula and 
expected probability of developing tolerance to cow’s milk by 18 months among non-igE-mediated allergic infants, generated by 100,000 iterations of the model.
Abbreviations: aaF, amino acid formula; ehCF, extensively hydrolyzed casein formula; hRF, hydrolyzed rice formula; inhs, italian national health service; lgg, 
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to the INHS of €0.35 million. The minimal difference in the 
budget impact of managing CMA over 12 and 18 months 
reflects the fact that most resources are used during the first 
12 months of management following the start of a formula.
Discussion
To our knowledge, this is the first health economic study to 
estimate the relative cost-effectiveness of using eHCF + LGG 
as first-line management for infants with CMA compared to 
eHCF, SBF, HRF, and AAF in Italy. Accordingly, the basis 
of the analysis was the only comparative dataset currently 
available.8 The advantage of using this observational  dataset 
is that the dietary effect was measured under controlled 
conditions. However, infants were not randomized to their 
formula, sample sizes were small in absolute terms and 
unbalanced between the groups, and resource use was not 
recorded. The study’s authors made every attempt to account 
for baseline differences between the groups and to overcome 
the nonrandomized study design. Differences in developing 
tolerance to cow’s milk between treatments were adjusted 
for any heterogeneity in baseline variables by the study’s 
authors. Additionally, we performed ANCOVA and found 
that no further adjustments were necessary. Nevertheless, 
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Figure 3 (A) Distribution of expected costs to parents over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months 
among igE-mediated allergic infants, generated by 100,000 iterations of the model. (B) Distribution of expected costs to parents over 18 months from starting a formula and 
expected probability of developing tolerance to cow’s milk by 18 months among non-igE-mediated allergic infants, generated by 100,000 iterations of the model.
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accounted for. The inherent variability and uncertainty of 
using data from this small and unequal sample of patients 
was addressed to some extent by our extensive sensitivity 
analyses. Notwithstanding this, power calculations showed 
that the sample sizes were sufficiently large to detect the 
observed differences, with 90% power and a Type I (alpha) 
error of 0.05 between the eHCF + LGG groups and the other 
groups, except the eHCF group among the infants with 
IgE-mediated CMA. The sample sizes in the IgE-mediated 
group fed with eHCF + LGG and eHCF had ,80% power 
to detect the observed differences between the two groups. 
The results from the observational study8 are consistent 
with another study that showed that in both IgE- and non-
IgE-mediated CMA, the addition of LGG to eHCF resulted 
in a higher rate of developing tolerance after 12 months of 
feeding.9 Additionally, we recently reported that in the US, 
significantly more eHCF + LGG-fed CMA infants in clinical 
practice were successfully managed compared with those 
who were fed with eHCF or AAF.14 There were no other 
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Figure 4 (A) Probability of being cost-effective at different cost-effectiveness thresholds for igE-mediated allergy infants, from the perspective of the inhs. (B) Probability 
of being cost-effective at different cost-effectiveness thresholds for non-igE-mediated allergy infants, from the perspective of the inhs.
Abbreviations: aaF, amino acid formula; ehCF, extensively hydrolyzed casein formula; hRF, hydrolyzed rice formula; inhs, italian national health service; lgg, 
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alternative formula for the management of CMA, except 
for our previous UK study.15 This UK study, which was also 
based on actual clinical practice, supports the current find-
ings that eHCF affords a cost-effective use of health care 
resources when compared to AAF.
In order to estimate the health economic benefit of devel-
oping tolerance at 12 months, the model was constructed over 
a period of 18 months. However, sensitivity analyses showed 
that inclusion/exclusion of the probability of developing 
tolerance to cow’s milk after 12 months has minimal impact 
on the results, since the majority of resources associated with 
managing infants with CMA are used in the first 12 months 
following diagnosis.
While the study results are compelling, the model may 
not necessarily reflect clinical outcomes associated with 
managing a large cohort of infants in clinical practice. 
Hence, the results should be viewed with some caution until 
more data become available which can be used to update the 
model. In particular, this study’s findings should provide 
a framework for a randomized, controlled study to measure 
the cost-effectiveness of tolerance development in children 
receiving a probiotic-containing formula compared to other 
formulae.
The study has several other limitations. The model was 
informed with assumptions about treatment patterns from 
pediatricians based at five centers. Hence, the levels of health 
care resource use may not be indicative of Italy as a whole. 
There was insufficient published clinical evidence to enable 
us to extrapolate the model beyond 18 months. Therefore, 
the analysis estimated the cost and consequences of man-
aging infants up to 18 months and does not consider the 
potential impact of managing infants who continue to suffer 
from CMA beyond that period. Infants in the observational 
study8 were well matched and those with comorbidities 
were excluded. Hence, the model used resource estimates 
for the “average infant” and does not consider the impact 
of other factors that may affect the results, such as comor-
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Figure 5 (A) Probability of being cost-effective at different cost-effectiveness thresholds for igE-mediated allergy infants, from parents’ perspective. (B) Probability of being 
cost-effective at different cost-effectiveness thresholds for non-igE-mediated allergy infants, from parents’ perspective.
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underlying disease. Additionally, the analysis does not take 
into account the suitability of infants to receive different 
formulae. The model only considered direct health care costs 
borne by payers and excluded indirect costs incurred by 
society as a result of employed parents taking time off work. 
Also excluded are changes in quality of life and improve-
ments in general well-being of sufferers and their parents 
as well as parents’ preferences. Consequently, this study 
may have underestimated the relative cost-effectiveness of 
eHCF + LGG.
Despite these limitations, the model shows that over 
the first 18 months, proportionally more infants fed with 
eHCF + LGG than with the other formulae would develop 
tolerance to cow’s milk. Consequently, they cost the health 
service less to manage and the cost incurred by parents for 
the formulae is less. This is an expected finding since, accord-
ing to the interviewed pediatricians, infants who develop 
 tolerance to cow’s milk would no longer require any manage-
ment or feeding with a hypoallergenic formula. Accordingly, 
treating the annual cohort of 16,000 new CMA-affected 
infants in Italy with eHCF + LGG instead of the current mix 
of formulae could increase the percentage of infants devel-
oping tolerance to cow’s milk from 52% to 84% and free up 
5,300 visits to pediatricians and reduce health service costs by 
up to €0.35 million. Clearly, initial use of eHCF + LGG has 
the potential to release health care resources for alternative 
use within the system.
LGG administration is associated with a complex 
response in intestinal mucosa, reflected by the up- and 
downregulation of several genes involved in immune 
response, inflammation, cell–cell signaling, signal tran-
scription, and transduction.16 Additionally, LGG is known 
to modulate immune functions via various pathways17–20 
to alter cytokine levels that may be involved in IgE- or 
non-IgE-mediated CMA, thereby modulating the major 
pathways involved in CMA pathogenesis17–21 and to alter 
the composition of the intestinal microbial community 
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associated with less development of allergy and atopy.22 
Moreover, in infants with CMA, the addition of LGG to 
eHCF compared with eHCF alone has been shown to more 
effectively attenuate increased intestinal permeability, and 
to decrease fecal calprotectin and the persistence of occult 
fecal blood losses.23,24
In conclusion, within the limitations of the observational 
dataset, first-line management of newly diagnosed infants 
Table 2 sensitivity analyses
Scenario Formula Range in expected  
probability of  
developing tolerance  
to cow’s milk
Range in expected  
INHS costs














assume no more infants develop  
tolerance to cow’s milk after  
12 months








































assume no incremental  
improvement after 6 months and  
no more infants develop tolerance  
to cow’s milk after 12 months
ehCF + lgg 0.65–0.30 0.95–0.85 €220–260 €100–140 €2,100–2,700 €1,600–2,300
ehCF 0.35–0.10 0.75–0.40 €240–270 €110–140 €2,600–2,900 €2,100–2,700
sBF 0.20–0.10 0.45–0.20 €250–270 €120–140 €2,200–2,300 €2,000–2,200
hRF 0.15–0.10 0.65–0.55 €260–270 €130–140 €2,300–2,400 €1,900–2,100
aaF 0.00–0.00 0.45–0.25 €260–270 €130–140 €4,700–4,800 €4,100–4,500
The number of follow-up visits  
to a pediatrician ranges from  
50% below to 50% above the  
base case value
























hRF Unchanged  
from baseline 
 Unchanged  
from baseline












The number of follow-up visits  
to a pediatric specialist ranges  
from 50% below to 50% above  
the base case value








































The number of diagnostic tests  
ranges from 50% below to  
50% above the base case value








































Abbreviations: aaF, amino acid formula; ehCF, extensively hydrolyzed casein formula; hRF, hydrolyzed rice formula; inhs, italian national health service; lgg, 
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ehCF containing lgg in managing cow’s milk allergy in italian infants
with CMA with eHCF + LGG instead of eHCF, SBF, HRF, 
or an AAF improves outcome, releases health care resources 
for alternative use, reduces costs to the INHS, affords 
a cost- effective use of publicly funded resources, and is cost-
effective from the parents’ perspective. Hence, eHCF + LGG 
is the preferred first-line formula for newly diagnosed infants 
compared to the other dietetic choices. However, a random-
ized controlled study showing faster tolerance development in 
children receiving a probiotic-containing formula is required 
before this conclusion can be confirmed.
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